share_log

康希諾生物：自願公告 - 重組脊髓灰質炎疫苗於印度尼西亞獲得臨床試驗批准

CANSINOBIO: VOLUNTARY ANNOUNCEMENT - GRANT AGREEMENT OF RECOMBINANT POLIOMYELITIS VACCINE AND RELATED COMBINED VACCINE PROJECT

HKEX ·  Oct 9 16:31

Summary by Futu AI

康希诺生物宣布，其研發中的候選疫苗CS-2036，已進入I/II期臨床試驗階段。該疫苗採用VLP（病毒樣粒子）技術平台開發，旨在針對多種病原體提供保護。康希诺生物的CEO Xuefeng YU和首席科學官Shou Bai CHAO將領導這項臨床試驗。試驗預計將於2024年10月9日完成。
康希诺生物宣布，其研發中的候選疫苗CS-2036，已進入I/II期臨床試驗階段。該疫苗採用VLP（病毒樣粒子）技術平台開發，旨在針對多種病原體提供保護。康希诺生物的CEO Xuefeng YU和首席科學官Shou Bai CHAO將領導這項臨床試驗。試驗預計將於2024年10月9日完成。
CanSino Biologics announced that its in-development candidate vaccine CS-2036 has entered the Phase I/II clinical trial stage. The vaccine is developed using VLP (virus-like particle) technology platform, aiming to provide protection against multiple pathogens. CanSino Biologics' CEO Xuefeng YU and Chief Scientific Officer Shou Bai CHAO will lead this clinical trial. The trial is expected to be completed on October 9, 2024.
CanSino Biologics announced that its in-development candidate vaccine CS-2036 has entered the Phase I/II clinical trial stage. The vaccine is developed using VLP (virus-like particle) technology platform, aiming to provide protection against multiple pathogens. CanSino Biologics' CEO Xuefeng YU and Chief Scientific Officer Shou Bai CHAO will lead this clinical trial. The trial is expected to be completed on October 9, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Related Stocks Related Stocks
    Symbol Mini Chart Latest Price
    YZYBIO-B
    02496
    -- 6.190
    3D MEDICINES
    01244
    -- 3.340
    CARSGEN-B
    02171
    -- 9.080
    FRONTAGE
    01521
    -- 1.700
    BRII-B
    02137
    -- 1.020

    Unlock the Full List